Dynavax Technologies Corp.
| Nasdaq: DVAX
Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. The company's other products under pipeline are DV1179 (TLR Inhibitor for Lupus) and AZD1419 (Asthma Therapy). Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.